This tiny colonial square is a perfect jumping-off point for exploring the heart of La Candelaria, with a wealth of shops, bars, and restaurants just a short walk away
The September 2025 expiry opens a new competitive window for both generic manufacturers and innovators developing genuinely differentiated epinephrine delivery technologies
evoke and evoke+: Design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimers disease
The period for patent protection for semaglutide in India will end in March 2026, opening the gates for generic competition
Larger standardized studies are warranted to validate and extend the present findings